ECO: New weight loss drug effective in advanced obesity

ECO: new weight loss drug effective in advanced obesity

(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, according to a study presented at the European Congress on Obesity, held from May 9 to 11 in Lyon, France.

Stephan Rössner, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues randomly assigned 2,487 subjects to placebo or one of two doses of PHEN/TPM CR: 7.5 mg/46 mg (7.5/46) or 15 mg/92 mg (15/92) for 56 weeks. Subjects were categorized according to the Edmonton Staging System (EOSS), which measures obesity-related morbidity, with most subjects having weight-related chronic disease (2,170 individuals) or established end-organ damage (180 individuals).

The researchers found that PHEN/TPM treatment was associated with significantly greater compared with placebo across all EOSS categories. Weight loss increased in a dose-response manner and ranged from 1.5 to 2.3 percent for placebo, 6.8 to 8.6 percent for 7.5/46 PHEN/TPM, and 9.5 to 10.5 percent for 15/92 PHEN/TPM. Dry mouth, constipation, and paraesthesia were the most common adverse events.

"In this study, subjects with established comorbidities treated with PHEN/TPM CR showed significantly greater weight loss than regardless of baseline EOSS," Rossner and colleagues conclude.

Several authors disclosed financial ties to pharmaceutical companies, including Vivus, which manufactures phentermine/topiramate and funded the study.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Experimental drug achieves unprecedented weight loss

Apr 11, 2011

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers ...

Topiramate may have benefit as a weight-loss drug

Jun 06, 2011

The drug topiramate can help people lose weight as long as they can tolerate the side effects, according to authors of a new study that reviewed the medical literature. Brazilian researchers will present the results Saturday ...

New promising obesity drug may have huge potential

Oct 23, 2008

According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a ...

Dapagliflozin aids glycemic control in type 2 diabetes

Mar 20, 2012

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

19 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments